2026 Meet the Speakers

Meet The Speakers

Call for Abstracts
Program at a Glance
Scientific Program
Meet the Speakers

ISLB 2026 brings together the innovators and rising leaders who are defining the next decade of liquid biopsy. Our speakers represent the forefront of scientific discovery, clinical translation and technological advancement. Each contributing a unique perspective with exceptional insights and bold ideas at the congress.

Maria Arechederra

Workshop Biological Fluids: Pre-analytical Issues

Maria Arechederra

María Arechederra holds a PhD in Pharmacy from Complutense University of Madrid. After research stays in Pennsylvania and Marseille, she joined Cima-University of Navarra, leading projects on liquid biopsy strategies for liver cancer. In 2026, she received the AEEH Rising Star Award for her contributions to hepatology field.

Maria Arechederra

CIMA-Universidad de Navarra

Spain

Maria Arechederra

CIMA-Universidad de Navarra

Beatriz Bellosillo

Hospital del Mar

Spain

Beatriz Bellosillo

Hospital del Mar

Beatriz Bellosillo is the head of the Molecular Biology Laboratory in the Pathology Service at Hospital del Mar, Barcelona, an associate professor at Pompeu Fabra University, Barcelona, and a group leader in the Cancer Research Program at the Hospital del Mar Research Institute. Her scientific interests in recent years have focused on the evaluation of molecular biomarkers involved in hematological malignancies and solid tumors, with particular emphasis on liquid biopsy.

Jacob Berchuck

Emory University School of Medicine

United States

Jacob Berchuck

Emory University School of Medicine

Dr. Jacob Berchuck is an Assistant Professor at Emory University School of Medicine and Medical Oncologist at the Winship Cancer Institute. In addition to caring for men with prostate cancer, he leads a research program focused on using liquid biopsy to investigate the molecular mechanisms of therapeutic response and resistance.

Silvia Calabuig

University of Valencia

Spain

Silvia Calabuig

University of Valencia

Silvia Calabuig Fariñas, PhD, is a lecturer at the Universitat de València and coordinator of the Liquid Biopsy Section at the Molecular Oncology Laboratory (eOM Group). Her research focuses on liquid biopsy and precision oncology in solid tumors. She leads the BLOOP group and is a member of CIBERONC. ORCID: 0000-0001-7749-174X.

Jenna Canzoniero

Johns Hopkins

United States

Jenna Canzoniero

Johns Hopkins

Breast medical oncologist and translational researcher focused on improving patient outcomes by developing novel uses for liquid biopsy to guide breast cancer diagnosis and treatment.

Massimo Cristofanilli

Weill Cornell

United States

Massimo Cristofanilli

Weill Cornell

MASSIMO CRISTOFANILLI, MD, is an accomplished board-certified medical oncologist with more than 2 decades of experience as physician, investigator, researcher and visionary leader. He demonstrated original and innovative vision in the field of molecular diagnostics, liquid biopsy, translational research and drug development. He has extensive background in clinical trial design and leadership in the field of metastatic and locally advanced breast cancer. He collaborated with Industry partners contributing to the design of trials submitted for regulatory approval, including Pfizer (palbociclib), GSK (lapatinib) and, most recently Lilly (abemaciclib). He serves as standing member of ODAC. Massimo is known for his pioneer work on circulating tumor cells (CTCs) that initiated the field of liquid biopsy and currently still leads a research laboratory performing correlative studies for various clinical trials in advanced solid tumors. This work now recognized among the most important milestones in cancer research (www.nature.com/articles/d42859-020-00070-z). He continued to expand his translational and clinical research portfolio setting up and coordinating a number of partnerships with diagnostic entities including, Guardant Health, Tempus, Foundation Medicine and Predicine. He was among the first investigators to describe the role of ESR1 mutations in endocrine resistance. He is Past President of the International Society of Liquid Biopsy (ISLB). He created and lead the Precision Medicine Clinical and Research Program at NMH, including a weekly MTB and a DT program, aimed at implementing and matching molecular diagnostics and novel therapeutics for clinical care. He is the Scientific Director of The Englander Institute of Precision Medicine (EPIM) in NY. Massimo is an internationally recognized expert in Inflammatory Breast cancer (IBC), founder and President of the IBC International Consortium (IBC-IC). He is a productive clinical investigator. His extensive original collaborative work with AZ, GSK and Pfizer resulted in original and practice change trials and high-impact manuscripts primarily focused on hormone-receptor positive MBC and IBC. He co-authored > 400 original manuscripts (H-index:105). He received is MD from The University “La Sapienza” in Rome and completed his fellowship training at the same University and subsequently at the UT-M D Anderson Cancer Center where he also served as Faculty in the Department of Breast Medical Oncology for more than a decade. He held several leadership position afterwards including Chairman of Medical Oncology and Associated Director of Clinical Research at the Fox Chase Cancer Center, Associated Director of Translational Research at TJU and NU.

Partha Das

JnJ

United States

Partha Das

JnJ

Partha M. Das, MD, is a Pathologist and Precision Medicine executive with 20+ years leading diagnostics strategy across pharma and medical devices. He has delivered five FDA CDx approvals, led the first liquid biopsy CDx launch globally, and currently advises on AI-powered computational pathology platforms advancing oncology diagnostics. He brings a pathologist's scientific foundation from clinical practice to building a strategic vision for delivering precision medicine and novel diagnostic solutions to healthcare systems, global pharma, and the diagnostics industry

Marta Dueñas

CIEMAT Madrid

Spain

Marta Dueñas

CIEMAT Madrid

Marta Dueñas heads the Molecular and Translational Oncology Research Group on Genitourinary Tumours at the Hospital 12 de Octubre-CIEMAT Foundation. Her work over the last 10 years has focused on the use of liquid biopsy for the development of diagnostic and prognostic biomarkers and prediction of response to therapies in bladder and renal cancer.

Tasneem Habib-Ishaq

AstraZeneca

United States

Tasneem Habib-Ishaq

AstraZeneca

At AstraZeneca Medical Diagnostics, I lead programmes to accelerate diagnostic innovation in oncology, having spearheaded a European liquid biopsy adoption initiative to scale CDx implementation and real world uptake. I bring 15+ years’ experience across industry and diagnostics: previously at Roche Diagnostics UK and US, where I led global CDx commercialisation for lung therapies, and as Head of Roche Dx Middle East, expanding access across emerging markets. I am passionate about liquid biopsy in lung cancer, championing its ability to revolutionise patient management through minimally invasive testing, rapid turnaround, and earlier access to the right therapies. Outside work, I fundraise through mountaineering, including Everest and K2, and will trek the Great Wall of China in support of cancer charities.

Michal Harel

OncoHost

United States

Michal Harel

OncoHost

Michal Harel, PhD, is a computational biologist specializing in proteomics and translational oncology. As VP of Translational Medicine at OncoHost, she leverages multi-omics data, machine learning, and biological insights to advance biomarker discovery and improve precision immunotherapy for patients with cancer.

Dennis Horgan

European Alliance for Perosnalised Medicine

Belgium

Dennis Horgan

European Alliance for Perosnalised Medicine

Prof. Denis Horgan, Ph.D., LLM, MSc, BCL studied law, economics, and political science in Ireland and the UK, completing postgraduate training in European regulatory affairs and health policy. He is the Founder and Executive Director of the European Alliance for Personalised Medicine (EAPM) in Brussels, uniting patients, professionals, industry, and policymakers to advance personalised medicine. Dr. Horgan has contributed to major EU initiatives, including the Council Conclusions on Personalised Medicine, the Cross-Border Healthcare Directive, the Innovative Medicines Initiative, the Million European Genomes Declaration, and the Biotech Act. His work focuses on the IVDR, EU Pharmaceutical Legislation reform, and the European Health Data Space. He has authored over 100 publications, including in Nature Medicine, JCO Global Oncology, and ESMO Open.

Ola Khorshid

National Cancer Institute, Cairo University

Egypt

Ola Khorshid

National Cancer Institute, Cairo University

Prof. Ola Khorshid is Professor and Chair of the Department of Medical Oncology at the National Cancer Institute (NCI), Cairo University. She is the Founder and Director of Millennium Healthcare, President of the Oncothoracic International Society (ONTiC), President of the Medical Oncology Research & Education Association (MORE–NCI), and Co-President of Women for Oncology Egypt. She also serves as a Steering Committee Member of the Egyptian Cancer Society. Internationally, she is an Executive Member of the International Society of Liquid Biopsy and a Faculty Member of the ASCO Mesothelioma Guidelines Committee (2024). She has played a leading role in developing cancer care protocols, launching Egypt’s first lung cancer screening program, and shaping national oncology policy. A dedicated mentor and educator, Prof. Khorshid has supervised numerous postgraduate theses and published extensively in thoracic oncology. She continues to advocate for equitable access to cancer care globally.

Rafael Lopez Lopez

Hospital Clinico de Santiago de Compostela

Spain

Rafael Lopez Lopez

Hospital Clinico de Santiago de Compostela

Rafael López López is the Head of the Oncology Department at the University Clinical Hospital of Santiago de Compostela (Spain), Director of the Translational Oncology Group at the Health Research Institute (IDIS), and Coordinator of the cancer area at the same institution (www.oncomet.es). He is also a Full Professor of Oncology at the Faculty of Medicine at the University of Santiago de Compostela. He earned his medical degree from the Autonomous University of Madrid. In 1988, he completed his training as a specialist in Medical Oncology at the General Hospital of Asturias. He was accredited by the European Society for Medical Oncology (ESMO) in 1989. He was an ESMO Fellow at the Free University Hospital of Amsterdam (Prof. HM Pinedo) in 1990 and 1991. He has worked at the Central Hospital of Asturias (Oviedo), the Hospital of Navarra (Pamplona), and founded and developed the Medical Oncology Department at the Txagorritxu Hospital (Vitoria). Since 1997, he has led the medical oncology department in Santiago de Compostela. He is deeply involved in research, having led over 150 clinical trials as the principal investigator. He is responsible for translational research in solid tumors, particularly breast and gastrointestinal cancers. He is currently working on research projects aimed at understanding and treating the metastatic process. His group is a leader in liquid biopsy in Spain, with strong research and clinical capabilities. He has been a speaker in the Cancer Strategy of the Ministry of Health. Dr. López is a member of ASEICA (Spanish Association for Cancer Research), EACR, ESMO, the Spanish Society of Medical Oncology (SEOM), the American Society of Clinical Oncology (ASCO), and the American Association for Cancer Research (AACR). He was also the president of the Galician Society of Cancer, during which time the Galician Cancer Strategy was developed in collaboration with the Health Service of Galicia. He is the author of over 200 publications and book chapters, both national and international, and has presented research at national and international congresses. He has participated in more than 10 patents and 3 spin-offs. He served as president of the ECO Foundation (Excellence and Quality in Oncology) in 2021 and 2022 and is currently the vice president. He is the president-elect of ASEICA.

Fernando Lopez-Rios

Hospital Universitario 12 de Octubre

Spain

Fernando Lopez-Rios

Hospital Universitario 12 de Octubre

Fernando Lopez-Rios is the Chief of the Molecular Diagnostics Service at Hospital Universitario 12 de Octubre (Madrid). His main clinical and research expertise is in cancer biomarker testing. He is the 2023 recipient of the Mary J. Matthews Pathology & Transitional Research Award and the Chair of the IASLC Pathology Committee.

Nuria Malats

Spanish National Cancer Research Centre

Spain

Nuria Malats

Spanish National Cancer Research Centre

Núria Malats, MD, MPH, PhD, is the head of the Genetic and Molecular Epidemiology Group at the Spanish National Cancer Research Centre (CNIO), Madrid. Her research focuses on pancreatic and bladder cancers. She participates in large national and international studies by integrating multimodal data, including liquid biopsy omics data,

Clara Montagut

Hospital del Mar Barcelona

Spain

Clara Montagut

Hospital del Mar Barcelona

Clara Montagut is a medical oncologist and scientist focused on patient care and advancing precision medicine in colorectal cancer. She is Head of the GI Cancer Unit at Hospital del Mar, where she also serves as research Deputy Director and Professor of Medicine. She has led multiple academic trials and published extensively in high-impact journals.

Luis Montuenga

University of Navarra

Spain

Luis Montuenga

University of Navarra

Luis Montuenga Badía is a Senior Researcher in Molecular Cancer Biology at CIMA and Professor of Cell Biology at the Faculty of Medicine of the University of Navarra. In November 2025, he was elected as Fellow of the European Academy of Cancer Sciences. He currently teaches in the Biochemistry Degree program with a Biomedical focus at the University of Navarra. Hegraduated with a degree in Science from the University of Navarra in 1981, receiving the Extraordinary Award, and earned his doctorate in 1985. In 1989 and 1990, he pursued postgraduate studies at the Royal Postgraduate Medical School (Hammersmith Hospital) in London, funded by a grant from the Ministry of Universities. From 1995 to 1998, he was a visiting researcher at the Biomarkers and Prevention Research Branch of the National Cancer Institute (National Institutes of Health, NIH) in Bethesda, USA, funded by the NCI/NIH International Office. He has served as Head of the Department of Pathology, Anatomy, and Physiology (6 years), Vice Dean of Students (3 years), Dean of the Faculty of Science (9 years), and Vice Rector for Research (3 years) at the University of Navarra. He has overseen the Biomedical Biochemistry degree program at the University of Navarra and is a founding member of the Association of Deans of Biomedicine, Biomedical Sciences, and related fields. He served as Director of the Oncology Area at CIMA (10 years) and was responsible for its technological platforms (3 years). He is currently the Director of the Biomarkers, Screening, and New Targets in Lung Cancer (LUNGSEARCH) Laboratory within the Solid Tumor Program at CIMA and a member of the Multidisciplinary Lung Cancer Area at the University Clinic of Navarra Cancer Center (CCUN), accredited by the Organization of European Cancer Institutes (OECI). His research focuses on the search for new molecular tools for the diagnosis and treatment of lung cancer, based on the study of the molecular and cellular biology of this neoplasm in its various stages. He is currently focused on multi-omics approaches: genomics, proteomics, and radiomics, analyzed using artificial intelligence. He is the author of 244 articles in his field, 6 book chapters, as well as other articles for general audiences, interdisciplinary dialogue, etc. He has supervised 24 doctoral theses and is currently supervising another six. He has given lectures and presentations at numerous national and international congresses and seminars in the fields of molecular oncology, biomarkers, early cancer detection, etc. In the last 5 years, he has been invited to speak at 15 international meetings. Dr. Montuenga has been the principal investigator on more than 60 competitive national and international projects, including several European projects, as well as on more than 20 collaborations with various pharmaceutical and biotechnology companies. He has been a member of the European Early Lung Cancer Research Group (EU-ELCG) and a partner in the European Consortium CURELUNG for lung cancer genomics and epigenomics, and is currently a member of the EU-funded consortia SOLACE and SPACETIME. In 2021, he participated in the INTEGRAL project, an international collaborative project funded by the NIH, and was admitted as a member of the International Lung Cancer Consortium (ILCCO) to study biomarkers in the context of early lung cancer detection. He has registered six patents, one of which has been licensed to a Spanish biotechnology company. He has served on numerous project evaluation committees (19 international and 6 national agencies). He is a member of the Executive Committee and coordinator of the Respiratory Tract Tumor Program at the Spanish National Cancer Research Centre (CIBERONC) of the Carlos III Health Institute. He is a member of the Staging and Prognostic Factors Committee of the International Society for the Study of Lung Cancer (IASLC) and contributed to the International Lung Cancer Staging Guidelines (9th edition) in the Molecular Factors Subcommittee. He is an Associate Editor of the Journal of Thoracic Oncology (IF 20.1) and four other oncology journals. Throughout his teaching career, he has taught undergraduate and postgraduate subjects in the field of Molecular and Cellular Biology, Molecular Oncology, Biomedical Research Methodology, Developmental Biology, Histology and in the Core Curriculum of interdisciplinary studies. He has been awarded six ""sexenios"" (six-year officially accredited research periods) and one six-year period for knowledge transfer and innovation.

Laura Muinelo

Health Research Institute of Santiago de Compostela Fidis

Spain

Laura Muinelo

Health Research Institute of Santiago de Compostela Fidis

Head of the Liquid Biopsy Analysis Unit at The Health Reserach Institute of Santiago de Compostela, Co-PI of the CB16/12/00328 CIBERONC team and coordinator of the Liquid Biopsy Working Group from CIBERONC. She has over 17 years of experience in liquid biopsy, specializing in CTCs and cfDNA/ctDNA and developing preclinical models from fluid samples. She currently leads research on personalized tools for managing endometrial tumors.

Jean Francois Pouliot

Regeneron Pharmaceuticals

United States

Jean Francois Pouliot

Regeneron Pharmaceuticals

Worked on numerous innovative trials leading to innovative drug approvals in various tumor types. Dr. Pouliot received his degree for the University of Montreal in Human Physiology and a fellowship at McGill University in multidrug resistance. At Regeneron Pharmaceuticals, he leads the global medical affairs team for several molecules

Chamindie Punyadeera

Griffith University

Australia

Chamindie Punyadeera

Griffith University

Professor Chamindie Punyadeera is a Fellow of the Australian Academy of Technological Sciences and Engineering and serves as Deputy Director of the ARC MOBIUS. She is a leading expert in salivary diagnostics and has successfully commercialised her research through CancerDetect, which has received FDA Breakthrough Device designation.

Kevin Puylaert

Sophia Genetics

Switzerland

Kevin Puylaert

Sophia Genetics

Kevin Puylaert is Chief Sales Officer at SOPHiA GENETICS, where he has driven global expansion since 2016. He led the company’s entry into APAC, LATAM, and the US, and founded its Boston office. Kevin holds degrees in science and business engineering from the University of Leuven, Belgium

Luca Quagliata

Thermo Fischer

Swiss

Luca Quagliata

Thermo Fischer

Luca Quagliata is Vice President and Head of Medical and Scientific Affairs at Thermo Fisher Scientific, leading international teams and strategic partnerships in precision oncology. He is adjunct faculty at University of Heidelberg and Venture Partner at xGen Venture SGR. He holds a PhD in Vascular Medicine and BCMAS certification.

Mary Redman

Fred Hutch Cancer Center

United States

Mary Redman

Fred Hutch Cancer Center

Mary Redman is a Professor and biostatistician in the Clinical Research Division at the Fred Hutchinson Cancer Center. She has extensive experience in the design, conduct, analysis and reporting of phase II and III clinical trials, with a particular focus on lung cancer and incorporation of biomarkers into trial design.

Alessandro Russo

Humanitas University

Italy

Alessandro Russo

Humanitas University

Assistant Professor at the Humanitas University, Milan and medical oncologist at the Humanitas Istituto Clinico Catanese, Misterbianco, Catania, Italy Dr. Russo is a board-certified medical oncologist with interest in thoracic malignancies, immunotherapy and liquid biopsies.

Edgardo Santos

The Oncology Institute of Hope and Innovation

United States

Edgardo Santos

The Oncology Institute of Hope and Innovation

"Physician Lead, TOI Lung Cancer Center of Excellence Medical Director- Broward County, Florida Medical Oncology-Thoracic Clinical Associate Professor Charles E. Schmidt College of Medicine Florida Atlantic University President, Florida Society of Clinical Oncology (FLASCO)"

Daniel Stover

Ohio State University Comprehensive Cancer Center

United States

Daniel Stover

Ohio State University Comprehensive Cancer Center

Dr. Daniel Stover is Associate Professor of Internal Medicine in the Division of Medical Oncology at Ohio State University Comprehensive Cancer Center. His research focuses on application of computational approaches to improve outcomes for patients with cancer. He was named Fellow of the American Society of Clinical Oncology (FASCO) in 2023.

Roberto Borea

Ohio State University

United States

Roberto Borea

Ohio State University

I am a physician-scientist at The Ohio State University. I earned my medical degree and completed residency in Medical Oncology at the University of Genova, Italy, where I also began a PhD in translational research. My career has spanned multiple international experiences, including work in a Phase I clinical trial unit in Belgium, single-cell sequencing at Institut Curie in Paris, and immune-cell therapies (CAR-T) during fellowships in the U.S. and London. At OSU, I focus on liquid biopsy biomarkers in lung cancer, aiming to better understand treatment responses and resistance mechanisms. Leveraging my translational background, my vision is to develop accessible tools to further personalize cancer treatment.

Alfonso Calvo

CIMA, UNIVERSITY OF NAVARRA

Spain

Alfonso Calvo

CIMA, UNIVERSITY OF NAVARRA

Alfonso Calvo, PhD is PI at CIMA, director of the Department of pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona Spain. His research focuses on lung cancer

Diego de Miguel Perez

Genyo

Spain

Diego de Miguel Perez

Genyo

Diego de Miguel Perez is a postdoctoral researcher at the ibs Granada - Genyo Center, Spain. His research specializes on the discovery of liquid biopsy biomarkers, including extracellular vesicles and circulating tumor cells for early detection and the prediction of response to treatment in patients with non-small cell lung cancer.

Mev Dominguez

Norway

Mev Dominguez

Mev Domínguez Valentín, PhD, is an internationally acclaimed leader in hereditary cancer syndromes, with unrivalled expertise in Lynch syndrome, precision oncology, and the equitable implementation of genetic medicine across diverse healthcare settings. Since 2022 she has served as Principal Investigator of the Prospective Lynch Syndrome Database (PLSD), the world’s largest prospective cohort of mismatch-repair gene mutation carriers, and in 2025 she was appointed Coordinator of the flagship EU Horizon Europe project PREDI-LYNCH (2025–2030), which is developing non-invasive liquid-biopsy tests for early cancer detection in Lynch syndrome. As Project Group Leader in the Department of Tumour Biology at the Institute for Cancer Research, Oslo University Hospital, she drives translational partnerships with industry and clinical laboratories to move these assays toward clinical validation and routine use. Her scientific journey spans four continents. She earned her PhD summa cum laude in Oncology from AC Camargo Cancer Center, São Paulo (2006–2009), an MSc from the University of São Paulo, and a Bachelor’s degree in Biological Sciences (Cellular Biology and Genetics) from San Marcos National University, Lima. Postdoctoral training followed at Oslo University Hospital, the University of Bergen, Lund University, and Centre Jean Perrin, France. A passionate bridge-builder between high- and low-resource settings, Dr Domínguez Valentín has established genetic counselling networks across Latin America, dramatically expanding access to testing and follow-up care in middle-income countries. She has mentored bachelor, master’s, and doctoral students in Norway and Latin America, led the adaptation of international guidelines to resource-limited contexts, and secured major competitive grants as principal investigator in Norway, Peru, and multinational consortia. Since 2016 she has curated the InSiGHT international mismatch-repair gene variant database and spearheaded the global adoption of standardised variant-classification rules. Her work directly shapes clinical practice worldwide, including the European Hereditary Tumour Group (EHTG) Mallorca guidelines and ESGO consensus statements on endometrial cancer prevention in Lynch syndrome. With over 100 peer-reviewed publications in journals such as Lancet Oncology, Nature Genetics, Gut, and Journal of Clinical Oncology, she seamlessly integrates large-scale registry studies with translational and implementation science. Her recent research combines statistical genetics and bioinformatics to refine cancer-risk prediction using polygenic risk scores and rare modifiers, paving the way for truly individualised surveillance. Her contributions have earned prestigious recognition, including the 2023 Dr Ragnar Mørk Prize for Excellent Cancer Research (Norway), the 2023 Best Cancer Research Project in Medicine award (Fundación Hipólito Unanue, Peru), and designation as a Woman Researcher of the Peruvian Bicentenary (2021). Fluent in Spanish, Portuguese, English, Norwegian, and French, she is a sought-after speaker and programme organiser at major international congresses, an active voice in public and media outreach on hereditary cancer prevention, and a tireless advocate for precision prevention and global equity in genomic medicine. Mev Domínguez Valentín exemplifies scientific excellence fused with profound social impact — a transformative force in hereditary cancer research and care worldwide.

David Gandara

UC Davis Comprehensive Cancer Center

United States

David Gandara

UC Davis Comprehensive Cancer Center

David Gandara, Professor of Medicine Emeritus at the University of California, Davis. He is the co-director of the Center for Experimental Therapeutics in Cancer and Senior Advisor to the Director at UC Davis Comprehensive Cancer Center. He was recently appointed Adjunct Clinical Professor, Translational and Clinical Research Program at the University of Hawaii Cancer Center and Chief Medical Officer for International Society of Liquid Biopsy (ISLB) a non-profit organization dedicated to advancing the science and clinical application of liquid biopsy in cancer diagnosis and therapy. He is an internationally known clinician-scientist and lung cancer thought leader, and has published over 450 peer-reviewed papers. He has led many notable research projects in lung cancer including early therapeutics trials through an N01-sponsored award, cooperative group trials as past-chair of the SWOG Lung Committee, and multi-institutional translational science projects such as clinical director of the patient-derived xenograft (PDX) lung program in collaboration with The Jackson Laboratory Cancer Center. Dr. Gandara has been selected for many awards and honors including the lifetime Scientific Award from the International Association for Study of Lung Cancer (IASLC), the Team Science Award from the Addario Lung Cancer Foundation, and the Trajectory Achievement Award from the ISLB. He is current principal investigator for a National Cancer Institute UG1 award to UCDCCC for cancer clinical trials, co-leader of Lung MAP, a unique NCI-sponsored public-private partnership for new drug development in lung cancer, and is founding co-chair and current member of the NCI-directed Investigational Drug Steering Committee (IDSC). Dr. Gandara is past Editor-in-Chief of the journal Clinical Lung Cancer. He served as president of the IASLC from 2009-2011 and as treasurer from 2013-2017. He is a prior member of the board of directors and secretary-treasurer of ASCO. In 2017, Gandara received the Giants of Cancer Care Award in lung cancer.

Paul Hofman

IHU RespirERA

France

Paul Hofman

IHU RespirERA

ISLB 2026 Research Awardee

Paul Hofman, MD, PhD is Professor of Pathology, Head of the new Institut IHU RespirERA at Nice University Côte d'Azur, France. He is the Directeur of Laboratory of Clinical and Experimental Pathology at Nice Hospital

Han Wei Hou

Nanyang Technological University

Singapore

Han Wei Hou

Nanyang Technological University

Dr. Hou is an Associate Professor at Nanyang Technological University Singapore. His research interests include microfluidics blood diagnostics, organ-on-chips, and biomanufacturing. He has over 60 peer-reviewed journal publications and 15 patents/patent applications. His recent research accolades include World's Top 2% Scientists (By Stanford University) (2023-2025) and IAMBE Early Career Award (2022).

Daniel Kim

University of California

United States

Daniel Kim

University of California

Dr. Daniel Kim, PhD is an Assistant Professor at the University of California, Santa Cruz, a Research Scholar of the American Cancer Society, Co-Chair of the U.S. National Institutes of Health (NIH) Liquid Biopsy Scientific Interest Group, and Co-Chair of the International Society for Extracellular Vesicles (ISEV) RNA Task Force.

Natasha Leighl

Princess Margaret Cancer Centre

Canada

Natasha Leighl

Princess Margaret Cancer Centre

ISLB 2026 Gandara Clinical Research Awardee

Dr. Natasha Leighl is the Division Head of Medical Oncology and Hematology (DMOH) at the Princess Margaret Cancer Centre and the UHN-Sinai Health Department of Medicine. She holds the Daniel E. Bergsagel Chair in Medical Oncology, a joint UHN-University of Toronto Endowed Chair, and is Professor in the Department of Medicine and Adjunct Professor in the Institute of Health Policy, Management and Evaluation, at the University of Toronto. As a globally recognized expert in lung cancer precision medicine, diagnostics, clinical management, and drug development, Dr. Leighl has published over 450 peer-reviewed papers and been recognized as a Clarivate Highly Cited Researcher and ScholarGPS Highly Ranked Scholar. She previously led the Thoracic Medical Oncology Group at the Princess Margaret Cancer Centre from 2011 to 2025 and held the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development through the Princess Margaret Cancer Foundation from 2012 to 2025. Dr. Leighl has made significant contributions to lung cancer research and treatment, including leadership of international clinical trials, drug development and establishing the role of liquid biopsy in clinical care. She and her team continue to work to improve outcomes for patients and access to state of the art care in Canada and worldwide. She serves on numerous international committees including the Board of Directors of the International Association for the Study of Lung Cancer. She chairs multiple guideline groups including the ASCO Thoracic Guidelines Advisory Group, the ESMO Early-Stage Lung Cancer Guideline, the International Society of Liquid Biopsy (ISLB) Education Committee and is ISLB Secretary-Elect. In 2019, she received the ASCO Excellence in Teaching Award. Many of her trainees have gone on to oncology leadership roles around the world.

Evi Lianidou

University of Athens

Greece

Evi Lianidou

University of Athens

ISLB 2026 Lifetime Achievement Awardee

Dr. Evi Lianidou is Professor of Analytical Chemistry and Clinical Chemistry at the Department of Chemistry, University of Athens, Greece. Since 1998 Prof Lianidou’s lab is specializing on Liquid Biopsy Analysis, and especially on the Analysis of Circulating Tumor Cells (ACTC) and ctDNA. Her main research interests are on the development and clinical evaluation of: a) RNA-based assays for gene expression in CTCs, using RT-qPCR, RT-ddPCR and liquid bead arrays, b) DNA mutations in CTCs and ctDNA using ultrasensitive multiplex ddPCR, c) DNA methylation assays in CTCs and ctDNA using MSP and ddPCR, and d) analysis of circulatin cell free miRNAs. Dr. Lianidou has organized till now seven highly attended international meetings on liquid biopsy ACTC meetings, (latest: ACTC2025: www.actc2025.org) Dr Lianidou is President of the Hellenic Society of Liquid Biopsy (HSLB), an elected Board member of the European Association of Cancer Research (EACR), a member and CTC working group Leader in the European Liquid Biopsy Society (ELBS), a member of the International Society of Liquid Biopsy (ISLB) and serves on the Editorial Boards of many international journals. Dr. Lianidou served International Federation of Clinical Chemistry (IFCC) as an elected member and Chair of the Committee for Clinical Molecular Biology Curriculum (2014-2019, (www.ifcc.org/ifcc-education-division/emd-committees/c-cmbc/). Prof. Lianidou holds three patents on liquid biopsy tests and is an author of 203 publications, most of them on liquid biopsy.

Sergio Marchini

IRCCS, Humanitas Research Hospital

Italy

Sergio Marchini

IRCCS, Humanitas Research Hospital

Sergio Marchini was born in 1969 and graduated summa cum laude, in Biological Science, University of Milan in 1993. In 2000 he was awarded in advanced studies in Pharmacology, University of Pavia, Italy and in 2003 he got the Ph. D. degree at the Open University, London UK. From 2001 to 2021 he has a permanent position as researcher at the "Mario Negri" Institute for Pharmacological Research, Department of Oncology. Since 2011 he was appointed Head of Translational Genomic Unit, Laboratory of Cancer Chemotherapy. From 2021 up to now , he moved to Humanitas research Hospital (Rozzano, Italy) as Director of the Humanitas Genomic Facility, and head of Translational Genomic Unit. The two main areas of research activities are identification of molecular biomarkers for early diagnosis of ovarian cancer and use of liquid biopsy to track minimal residual disease over time and tumor evolution , in ovarian and mesothelioma patients.

Miguel Angel Molina

Hospital Universitario Dexeus

Spain

Miguel Angel Molina

Hospital Universitario Dexeus

Miguel Ángel Molina-Vila is the Technical Director of the Laboratory of Oncology at the Dexeus University Hospital, in Barcelona. From this position, he pioneered the implementation of liquid biopsy testing of cancer patients in Spain and is currently working in the development of RNA-based signatures in blood, among other projects.

Manuel Ottaviano

UNIVERSIDAD POLITECNICA DE MADRID

Spain

Manuel Ottaviano

UNIVERSIDAD POLITECNICA DE MADRID

Manuel Ottaviano is an Associate Professor at Universidad Politécnica de Madrid and a digital health expert. His research examines human–technology interaction and its impact on health and well-being. He coordinates the SPARC EU project, advancing Precision Cancer Medicine across Europe.

Klaus Pantel

University Medical Center Hamburg-Eppendorf (UKE)

Germany

Klaus Pantel

University Medical Center Hamburg-Eppendorf (UKE)

Prof. Dr. Klaus Pantel is Director of the Institute of Tumor Biology at the University Medical Center Hamburg-Eppendorf, Germany. The Institute is part of the Center for Experimental Medicine and the University Cancer Center (UCCH). Prof. Pantel graduated from the University of Cologne in 1986 and completed his dissertation in 1987 in the field of mathematical models of hematopoiesis. After his postdoctoral training in the USA at Wayne State University, Detroit, where he conducted research on hematopoietic stem cell regulation, he spent 10 years at the Institute of Immunology at the University of Munich, where he habilitated in 1995 in the field of experi-mental immunology and immunotherapies. Prof. Pantel's pioneering work in the field of micrometastasis and liquid biopsy (analysis of tumor components in the blood, e.g. circulating tumor cells and circulating nucleic ac-ids (ctDNA, microRNAs)) of solid tumors is reflected in more than 600 publications (h-factor 161) in excellent high-ranking biomedical and scientific journals (incl. NEJM, Lancet, Nature Journals, Cancer Cell, Science Trans-lational Medicine, Cancer Discovery, PNAS, JCO, JNCI, Cancer Res.). His research work has been recognized by the AACR Outstanding Investigator Award 2010, the German Cancer Award 2010, and four ERC Grants, among others. He is the Founder and current President of the European Liquid Biopsy Society (www.elbs.eu) and the Scientific Coordinator/Lead-PI of the EU consortia PANCAID (pancaid-project.eu/) and GUIDE-MRD (www. www.guidemrd-horizon.eu/).

Bruna Pellini

Baptist Health Miami Cancer Institute

United States

Bruna Pellini

Baptist Health Miami Cancer Institute

Dr. Bruna Pellini is Chief of Thoracic Medical Oncology at Baptist Health Miami Cancer Institute. A lung cancer specialist, she leads research in liquid biopsies for personalized cancer care. She has published extensively and serves in national leadership roles with the NIH, SWOG, and ASCO, advancing clinical trials and treatment strategies in oncology.

Jason Porter

Guardant Health

United States

Jason Porter

Guardant Health

Dr. Jason Porter is a Memphis-born thoracic medical oncologist and Vice President of Clinical Education at Guardant Health. Trained at the University of Tennessee Health Science Center, he previously cared for patients at West Cancer Center & Research Institute. His work centers on equitable access to molecular testing and translating genomic insights into better lung cancer care.

Carolina Reduzzi

Weill Cornell Medicine

United States

Carolina Reduzzi

Weill Cornell Medicine

Carolina Reduzzi is Assistant Professor of Cancer Biology Research in Medicine and Director of the Liquid Biopsy Platform at Weill Cornell Medicine. Her research focuses mainly on circulating tumor cells in breast cancer.

Atocha Romero

Hospital Puerta De Hierro

Spain

Atocha Romero

Hospital Puerta De Hierro

Atocha Romero is a leading researcher in translational oncology and has been the Director of the Liquid Biopsy Laboratory at Puerta de Hierro University Hospital since 2015. With over 100 scientific publications (25 in Q1–D1), she leads multiple competitive projects as Principal Investigator. She is an associate professor at CEU San Pablo University and has supervised several doctoral theses, two of which received awards. Her research focuses on the application of liquid biopsy in lung cancer patients and the detection of minimal residual disease (MRD) to personalize treatment.

Claudia Scimone

University of Naples, Federico II

Italy

Claudia Scimone

University of Naples, Federico II

I hold a Master’s degree in Medical Biotechnology and a postgraduate Master in Molecular Pathology. I completed a PhD in Public Health at the University of Naples, in the Predictive Molecular Pathology Laboratory, gaining expertise in applying NGS panels to analyze tissue samples and liquid biopsy specimens in clinical research.

Nikolas Stoecklein

University Hospital and Medical Faculty of the Heinrich Heine University Düsseldorf

Germany

Nikolas Stoecklein

University Hospital and Medical Faculty of the Heinrich Heine University Düsseldorf

Professor and Section Head of Experimental Surgical Oncology at Heinrich-Heine University Düsseldorf. His research focuses on minimal residual disease in solid tumors and circulating tumor cells (CTCs). Using diagnostic leukapheresis and single-cell profiling, his team advances liquid biopsy technologies to elucidate mechanisms of metastasis formation and improve therapeutic selection strategies.

Noelia Tarazona

INCLIVA Biomedical Research Institute

Spain

Noelia Tarazona

INCLIVA Biomedical Research Institute

Medical oncologist specialized in colorectal cancer, with a focus on precision oncology and liquid biopsy. Actively involved in translational research integrating ctDNA and biomarkers to guide treatment decisions. Contributor to international clinical research and scientific meetings, with a strong interest in advancing personalized cancer care and improving the sustainability of precision medicine.

Mathias Uhlén

KTH School of Engineering Sciences in Chemistry, Biotechnology

Sweden

Marc Van den Bulcke

Sciensano

Belgium

Marc Van den Bulcke

Sciensano

Marc Van den Bulcke heads Belgium’s Cancer Centre at Sciensano since 2013. He is involved in various collaborations at EC level through several Joint Actions and projects within the Europe's Beating Cancer Plan. A particular initiative is the introduction of ‘omics’ as tool in personalized medicine in oncology based on advances in translational research and public health.

Kenneth Witwer

Johns Hopkins University

United States

Kenneth Witwer

Johns Hopkins University

Kenneth Witwer is faculty at the Johns Hopkins University School of Medicine, where his laboratory studies extracellular vesicles and RNA. He is Immediate Past President of the International Society for Extracellular Vesicles.

Javier de Castro

Hospital La Paz, Madrid

Spain

Javier de Castro

Hospital La Paz, Madrid

Medical Oncologist focus on Lung Cancer Reaseach, President of Spanish Society of Medical Oncology

Aya El Halali

University of Hong Kong

China

Aya El Halali

University of Hong Kong

Professor Aya El Helali is a clinician scientist specializing in early-phase clinical trials, drug development, biomarkers, and genomics, with a particular focus on neuro-oncology. She recently joined the Department of Clinical Oncology at the University of Hong Kong, where she also serves as co-chair of the HKU-HKSH Molecular Tumor Board (MTB). Additionally, she is the First Vice President and Past President of the Hong Kong Neuro-Oncology Society

Paola Gazzaniga

University Sapienza

Italy

Paola Gazzaniga

University Sapienza

Paola Gazzaniga is Full professor of Precison Oncology and Director of the Laboratory of Liquid Biopsy at Sapienza University of Rome. She has contributed over 120 publications and book chapters. Her landmark work demonstrated the clinical utility of circulating tumor cells and circulating tumor DNA in breast , bladder and colorectal cancer. Through national and international collaborations, she is involved in several pilot and phase 2 studies aimed to definitely integrate liquid biopsies into clinical practice.

Eloisa Jantus Lewintre

Awards Lecture, European Research Projects in Liquid Biopsy & Workshop Biological Fluids

Eloisa Jantus Lewintre

Eloisa Jantus Lewintre is Full Professor of Cell Biology at the Universitat Politècnica de València and Principal Investigator of the Biomarkers in Cancer Group at the Joint CIPF–UPV Research Unit in Valencia, Spain. She currently serves as Vice President of the International Society of Liquid Biopsy (ISLB). Her research focuses on the development of advanced 3D lung cancer models and the discovery of novel biomarkers using liquid biopsy approaches, particularly circulating tumor DNA (ctDNA) to improve prognosis assessment, guide patient stratification, and monitor tumor–immune interactions. Dr. Jantus has authored over 100 peer-reviewed publications in journals such as Nature Communications, Annals of Oncology, and Journal of Thoracic Oncology. She is a frequent speaker at major international conferences and serves as reviewer and Section Editor for leading oncology journals.

Umberto Malapelle

Awards Lecture & Next-Generation Liquid Biopsy

Umberto Malapelle

Umberto Malapelle is Associate Professor and Head of a Molecular Pathology Laboratory at the University of Naples Federico II. He worldwide leader, pioneered clinical Next Generation Sequencing, developed the SiRe® panel, and serves as Editor-in-Chief of The Journal of Liquid Biopsy and President of the International Society of Liquid Biopsy.

Clara Mayo

Next-Generation Liquid Biopsy

Clara Mayo

Dra Clara Mayo holds a PhD in Biological Sciences from Pompeu Fabra University, Barcelona and has over 25 years’ experience in translational cancer research, basically focused on analysis of molecular biomarkers with clinical applications in circulating free DNA of cancer patients. She has coauthored more than 55 publications in renowned scientific journals. She is a member of AACR (American Association for Cancer Research), GEM (Spanish Melanoma Group), ISLB (International Society of Liquid Biopsy), currently serves as the group's treasurer. Holds the position of Laboratory Operations Director at Pangea oncology laboratory.

Luis Raez

Preferred Oral Abstract Session

Luis Raez

Luis E. Raez, MD, FASCO, FACP works as Chief Scientific Officer & Medical Director of the Memorial Cancer Institute (MCI)/Memorial Health Care System, He is Co-Director of the MCI/FAU Florida Cancer Center of Excellence designated by the Florida Department of Health, one of only six cancer centers in Florida. He is also Director of the Thoracic Oncology Program. He is also Clinical Professor of Medicine at Florida International University (FIU), Visiting Professor of Medicine at Cayetano Heredia University in Peru and Research Professor at Florida Atlantic University (FAU). He was President of the Florida Society of Clinical Oncology (FLASCO) 2019-2021.

Christian Rolfo

Stakeholder Workshop

Christian Rolfo

Christian Rolfo, MD, PhD, MBA, Dr.hc. is Professor of Medicine at the Ohio State University, School of Medicine. He is serving as Division Director of Medical Oncology and Associate Director for Early Phase Clinical Trials at The James Comprehensive Cancer Center at OSU, in Columbus, OH. Before joining OSU, he was serving as Professor at Mount Sinai School of Medicine and Associate Director for Clinical Research in the Center for Thoracic Oncology at The Tisch Cancer Institute. Dr. Rolfo’s clinical and research focus is on drug development, lung cancer and other thoracic malignancies, biomarkers, resistant mechanisms discovery, and liquid biopsies. Dr. Rolfo has held academic appointments at numerous institutions, including the University of Cordoba, Argentina; University of Antwerp, Belgium; University of Palermo, Italy, and the University of Maryland and Greenbaum Comprehensive Cancer Center where he was Director of Thoracic Medical Oncology and Director of Early Clinical Trials. Dr. Rolfo earned his MD at the University of Cordoba School of Medicine, his PhD and Doctor Europaeus in Clinical and Experimental Oncology Research at University of Palermo, Italy, and an MBA in Hospital and Health Services Management and Organization at Polytechnic University of Valencia, Spain. He completed residency training in Medical Oncology at the National Cancer Institute in Milan (University of Milan, Italy). Dr. Rolfo is President of the International Society of Liquid Biopsy (ISLB) and Chair of the Education Committee at the International Association for Study of Lung Cancer (IASLC). Dr. Rolfo served as member of the Drug Approval & First in Human Commission at the Ministry of Health in Belgium during his time as Phase I Director at Antwerp University. Dr. Rolfo is actively working on drug development and lung cancer and mesothelioma treatment. His research is focused in molecular oncology, targeted therapies and Immunotherapy in thoracic oncology using new techniques in liquid biopsies, specifically in extracellular vesicles and circulating free tumor DNA. His research group identified ALK translocation in exosomes in NSCLC patients, and showed, for the first time, the videos of labeled EVs uptake by living lung cancer cells. He is currently working on the identification of new biomarkers involved in immunotherapy and TKI drug-resistance and early detection of lung cancer with liquid biopsy. Dr. Rolfo has contributed to the development of several compounds including Erlotinib, and the pharmacokinetics of Olaparib, Entrectinib, Selpercatinib, Trastuzumab Duocarmazine, among others. Dr. Rolfo has authored more than 350 scientific articles, has made several contributions to book chapters, and has served as a book editor. He has published extensively in peer-reviewed journals including New England Journal of Medicine, Lancet Oncology, Cancer Discovery, Nature Clinical Reviews in Oncology, Journal of Thoracic Oncology, Nature Nanotechnology, Clinical Cancer Research, Annals of Oncology, and Lung Cancer among others. Dr. Rolfo is Editor in Chief of Critical Review in Oncology Hematology.

María José Serrano

Evolving and Future Methodologies in Liquid Biopsy

María José Serrano

Principal Investigator of the Liquid Biopsy and Cancer Interception (LiqBiopCI) group at Virgen de las Nieves University Hospital and the GENyO center in Granada. I am also an associate professor in the Department of Pathological Anatomy at the University of Granada. My career has been dedicated to cancer research, with a primary focus on the field of liquid biopsy. I have undertaken various research visits both within Spain (Basque Country, Catalonia, Madrid) and abroad (Tromso, Norway). I am the author of over 100 articles, the majority of which center around liquid biopsy research. My work has been published in prestigious journals such as Lancet, Annals of Oncology, and Cancer Discovery. I lead both national and international research projects. Currently, I am overseeing a national project funded by the European Commission and the Ministry of Innovation and Technology of Spain. This project aims to facilitate the clinical implementation of liquid biopsy in Andalusian Hospitals through the Innovative Public Procurement program. Notably, the outcomes of these projects have led to internationally licensed patents. I am a co-founder and currently hold the position of Vice President at the International Society for Liquid Biopsy (ISLB). Moreover, I serve as the coordinator of PANMEP, the Andalusian Precision Medicine program, which is sponsored by the Ministry of Health of Andalucia. This program is dedicated to training clinical personnel in new diagnostic methodologies. Additionally, since 2022, I have held the role of Innovative Health Andalusia Public Procurement Coordinator. Furthermore, I am an Associate Editor at CROH and Frontiers in Cell and Developmental Biology, as well as at the Journal of Liquid Biopsy (JLB).

Yüksel Ürün

Preferred Oral Abstract Session

Yüksel Ürün

Dr. Yüksel Ürün is a Professor of Medical Oncology at Ankara University, specializing in genitourinary cancers. He is work in precision oncology, active in TKCC, EORTC, ISLB, APCCC, ASCO and ESMO. His work bridges research and advocacy, with a focus on biomarkers, equity, and international collaboration.

Konstantinos Venetis

Workshop Biological Fluids

Konstantinos Venetis

Konstantinos Venetis, PhD is a senior scientist coordinating the R&D group within the Division of Pathology at the European Institute of Oncology (IEO) IRCCS, Milan. His research focuses on breast cancer biomarkers, integrating molecular profiling, liquid biopsy, and digital pathology. He has authored over 80 publications and contributes to initiatives of the International Society of Liquid Biopsy.

Jacob Berchuck

Emory University School of Medicine

United States

Jacob Berchuck

Emory University School of Medicine

Jenna Canzoniero

Johns Hopkins

United States

Jenna Canzoniero

Johns Hopkins

Breast medical oncologist and translational researcher focused on improving patient outcomes by developing novel uses for liquid biopsy to guide breast cancer diagnosis and treatment.

Javier de Castro

Hospital La Paz, Madrid

Spain

Javier de Castro

Hospital La Paz, Madrid

Medical Oncologist focus on Lung Cancer Reaseach, President of Spanish Society of Medical Oncology

Nicola Fusco

European Institute of Oncology

Italy

Nicola Fusco

European Institute of Oncology

Prof. Nicola Fusco is Full Professor of Pathology at the University of Milan and Head of the Division of Pathology and Somatic Molecular Diagnostics at the European Institute of Oncology in Milan. He co-chairs of the ISLB Quality Control and Accreditation Committee.

David Gandara

UC Davis Comprehensive Cancer Center

United States

David Gandara

UC Davis Comprehensive Cancer Center

Paola Gazzaniga

University Sapienza

Italy

Paola Gazzaniga

University Sapienza

Aya El Halali

University of Hong Kong

China

Aya El Halali

University of Hong Kong

Paul Hofman

IHU RespirERA

France

Paul Hofman

IHU RespirERA

Natasha Leighl

Princess Margaret Cancer Centre

Canada

Natasha Leighl

Princess Margaret Cancer Centre

Eloisa Jantus Lewintre

Polytechnic University of Valencia

Spain

Eloisa Jantus Lewintre

Polytechnic University of Valencia

Umberto Malapelle

University Of Naples- Federico II

Italy

Umberto Malapelle

University Of Naples- Federico II

Clara Mayo

Hospital Universitario Dexeus. Pangaea Oncology Laboratory

Spain

Clara Mayo

Hospital Universitario Dexeus. Pangaea Oncology Laboratory

Luis Raez

Memorial Cancer Institute/Florida Atlantic University

United States

Luis Raez

Memorial Cancer Institute/Florida Atlantic University

Christian Rolfo

Diane Nye and Michael Rayden Chair in Innovative Cancer Research

United States

Christian Rolfo

Diane Nye and Michael Rayden Chair in Innovative Cancer Research

María José Serrano

University Hospital Virgen de las Nieves

Spain

María José Serrano

University Hospital Virgen de las Nieves

Yüksel Ürün

Ankara University School of Medicine; Department of Medical Oncology

Turkey

Yüksel Ürün

Ankara University School of Medicine; Department of Medical Oncology

Konstantinos Venetis

IEO - European Institute of Oncology

Italy

Konstantinos Venetis

IEO - European Institute of Oncology

Paul Hofman

IHU RespirERA

France

Paul Hofman

IHU RespirERA

Evi Lianidou

University of Athens

Greece

Evi Lianidou

University of Athens

Natasha Leighl

Princess Margaret Cancer Centre

Canada

Natasha Leighl

Princess Margaret Cancer Centre

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.